Clinical trials using anti-CD5 monoclonal antibody have revealed a moderate therapeutic effect in patients with cutaneous T cell lymphomas (CTCLs) or chronic lymphocyte leukemia (CLL) [29, 30]. Here, CD5 is linked to B-cell chronic lymphocytic leukemia.